PO-REN HSUEHHo, Sung-JungSung-JungHoHsieh, Po-ChuenPo-ChuenHsiehLiu, I-MinI-MinLiuJean, Shio-ShinShio-ShinJean2024-02-072024-02-0720231687-966Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/639684Acute respiratory distress syndrome (ARDS) is a critical complication in severe COVID-19 patients. The intravenous infusion (IVF) of umbilical cord- (UC-) mesenchymal stem cells (MSCs), validated to substantially reduce the release of several inflammatory cytokines in vivo, was also shown to exhibit benefits in improving hypoxemia among severe COVID-19 patients. A single dose of IVF-UC-MSCs therapy for severe COVID-19 patients was shown to alleviate the initial ARDS severity, but have 50%-67% case-fatality rates. In Taiwan, few adult patients with severe COVID-19-induced ARDS receiving compassionate adjuvant treatment consisting of either a single dose (1-10 × 106 cells/kg body weight (kg BW)) or three doses (5 × 106 cells/kg BW in each dose) of IVF-UC-MSCs had good outcomes. However, the optimal dosage and rounds of IVF-UC-MSCs administration for the treatment of severe COVID-19 patients with ARDS are undetermined.enreview10.1155/2023/7179592376383342-s2.0-85170575754https://api.elsevier.com/content/abstract/scopus_id/85170575754